CAL
SPRB

Capital Advisors Ltd’s Spruce Biosciences SPRB Stock Holding History

Capital Advisors Ltd’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8
Closed -$1K – 1710
2022
Q3 		$1K Buy
8
+6
+300% +$839 ﹤0.01% 1166
2022
Q2 		$0 Buy
+2
New +$256 ﹤0.01% 1382
2022
Q1 		– Sell
-3
Closed -$1K – 1261
2021
Q4 		$1K Buy
+3
New +$893 ﹤0.01% 771

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Capital Advisors Ltd's SPRB Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Spruce Biosciences (SPRB) in Q4 2022, closing a stake of 8 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in SPRB in Q4 2021 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 29 funds tracked by Wall St. Rank hold SPRB as of Q4 2022.

  • Capital Advisors Ltd reported no remaining Spruce Biosciences position as of Q4 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 8 Spruce Biosciences shares in Q4 2022, an estimated $1K.
  • Capital Advisors Ltd first reported a position in Spruce Biosciences in Q4 2021 and held it in 3 quarters.
  • Capital Advisors Ltd's Spruce Biosciences position peaked at $1K in Q3 2022.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.